Facial Wasting Rehabilitation: A Personal Algorithm
DOI:
https://doi.org/10.31907/2414-2093.2017.03.02Keywords:
Filler, facial lipoatrophy, structural fat graft, facial wasting, HIV.Abstract
Facial lipoatrophy, also known as facial wasting (FW), defined as flattening or indentation of normally convex facial contours, is the most distressing manifestation for HIV patients. It can be stigmatizing, severely affecting quality of life and self-esteem, and it may result in reduced antiretroviral adherence. Several surgical or non surgical techniques exists, however to restore facial features in HIV-related lipoatrophy fillers and structural fat graft seems2 to be the procedures most performed. In this article the authors present his experience in FW rehabilitation, and his decisional algorithm of choice.
References
Danner SA, Carr A, Leonard J, et al. Safety, pharmakinetics and preliminary efficacy of ritonavir, and inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-1533. https://doi.org/10.1056/NEJM199512073332303
Hammer SM, Squires KE, Hughs MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med 1997; 337: 725-733. https://doi.org/10.1056/NEJM199709113371101
Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000; 30(Suppl 2): S135-S142. https://doi.org/10.1086/313854
Waters L and Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract 2007; 61: 999-1014. https://doi.org/10.1111/j.1742-1241.2007.01385.x
Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39: 395-400. https://doi.org/10.1097/01.qai.0000167478.28051.3a
Carr A, Samaras K, Burton S, et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1 infected individuals. AIDS 1998; 12: F51-8. https://doi.org/10.1097/00002030-199807000-00003
Domingo P, Sambeat MA, Perez A, Ordonez J, Rodriguez J and Vazquez G. Fat distribution and metabolic abnormalities in HIVinfected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor. Antivir Ther 2003; 8: 223-31.
Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy. AIDS 1999; 13: 1659-67. https://doi.org/10.1097/00002030-199909100-00009
Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40: 121-31. https://doi.org/10.1097/01.qai.0000182230.47819.aa
John M, Nolan D and Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; 6: 9-20.
Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18: 2137-44. https://doi.org/10.1097/00002030-200411050-00005
Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral- naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201. https://doi.org/10.1001/jama.292.2.191
Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357: 592-8. https://doi.org/10.1016/S0140-6736(00)04056-3
Calza L, Manfredi R and Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53: 10-4. https://doi.org/10.1093/jac/dkh013
Jacobson DL, Jacobson DL, Knox T, et al. Prevalence of evolution of and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005; 40: 1837-45. https://doi.org/10.1086/430379
Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003; 4: 293-301. https://doi.org/10.1046/j.1468-1293.2003.00159.x
Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15: 1389-98. https://doi.org/10.1097/00002030-200107270-00008
Duran S, Saves M, Spire B, et al. Failure to maintain longterm adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15: 2441-2444. https://doi.org/10.1097/00002030-200112070-00012
Waters L and Nelson M. Long-term complications of antiretroviral therapy: Lipoatrophy. Int J Clin Pract 2007; 61(6): 999-1014. https://doi.org/10.1111/j.1742-1241.2007.01385.x
Fisher K. Wasting and lipodystrophy in patients infected with HIV: A practical approach in clinical practice. AIDS Read 2001; 11: 132.
Corcoran C and Grinspoon S. The use of testosterone in the AIDS wasting syndrome. AIDS Clin Care 1999; 11: 25.
Gold J and Battheram M. Nandrolone decanoate: Use in HIV-associated lipodystrophy syndrome: A pilot study (Letter). Int J STD AIDS 1999; 10: 558. https://doi.org/10.1177/095646249901000814
Hengge UR, Stocks K, Unger S, Faulkner S, Goos M and Dudley R. Randomized phase III trial of oxymetholone for the treatment of HIV wasting and lipodystrophy. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, Wash 2002; 24-28.
James J, Carruthers A and Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002; 28: 979-986.
Narins RS and Bowman PH. Injectable skin fillers. Clin Plast Surg 2005; 32: 151 https://doi.org/10.1016/j.cps.2004.12.002
Bechara FG, Gambichler T, Brockmeyer NH, et al. Hyaluronic acid new formulation: experience in HIVassociated facial lipoatrophy. Dermatology 2008; 217: 244-9. https://doi.org/10.1159/000148252
Woerle B, Hanke CW, Satteler G. Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol 2004; 3(4): 385Ð389.
Sherman RN. Sculptra: the new three-dimensional filler. Clin Plast Surg 2006; 33(4): 539-550.
Lowe NJ. Dispelling the myth: appropriate use of poly-L-lactic acid and clinical consideration. J Eur Acad Dermatol Venereol s1:2Ð6, 2006.
Rendon MI. Long-term aesthetic outcomes with injectable poly-l-lactic acid: observations and practical reccomendations based on clinical experience over 5 years. J Cosmet Dermatol 2012;11(2): 93-100. https://doi.org/10.1111/j.1473-2165.2012.00609.x
Ezzat WH and Keller GS. The use of poly-L-lactic acid filler in facial aesthetics. Facial Plast Surg 2011; 27(6): 503-9. https://doi.org/10.1055/s-0031-1298782
Douglas RM and Humble GM. Retreatment with injectable Poly-L-Lactic Acid for HIV-associated facial lipoatrophy: 24 months extension of the blue pacific study. Dermatol Surg 2009; 35: 350-359. https://doi.org/10.1111/j.1524-4725.2008.01047.x
Douglas RM and Humble GM. Safety and efficacy of Poly-LLactic Acid injections in the persons with HIV-associated lipoatrphy: The US experience. Dermatol Surg 2006; 32: 1336-1345.
Tzikas TL. Evaluation of Radiance FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg 2004; 6:34Ð239.
Graivier MH, Bass LS, Busso M, Jasin ME, Narins RS and Tzikas TL. Calcium Hydroxylapatite (Radiesse) for correction of the mid- and lower face: Consensus reccomendations. Plast Reconstr Surg 2007; 120(Suppl): 55S. https://doi.org/10.1097/01.prs.0000285109.34527.b9
Marmur ES, Phelps R and Goldberg DJ. Clinical, histologic, and electron microscopic findings after injection of a calcium hydroxylapatite filler. J Cosmet Laser Ther 2004; 6: 223-226. https://doi.org/10.1080/147641704100003048
Alam M and Yoo SS. Technique for calcium hydroxylapatite injection for correction of nasolabial fold depressions. J Am Acad Dermatol 2007; 56: 285-289. https://doi.org/10.1016/j.jaad.2006.09.014
Carruthers A, Liebeskind B, Carruthers J and Forster BB. Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV- associated facial lipoatrophy and correction of naso- labial folds. Dermatol Surg 2008; 34: S78-S84. https://doi.org/10.1097/00042728-200806001-00017
Rauso R, Curinga G, Rusciani A, Colella G, Amore R and Tartaro G. Safety and efficacy of one-step rehabilitation of human immunodeficiency virus-related facial lipoatrophy using an injectable calcium hydroxylapatite dermal filler. Dermatol Surg 2013; 39(12): 1887-94. Epub 2013 Nov 7. https://doi.org/10.1111/dsu.12358
Kolle F. Plastic and Cosmetic Surgery. New York: Appleton 1911; 209-230.
Rapaport MJ, Vinnik C and Zarem H. Injectable silicone: Cause of facial nodules, cellulitis, ulceration, and migration. Aesthetic Plast Surg 1996; 20: 267. https://doi.org/10.1007/s002669900032
Ersek RA and Beisang AA. III. Bioplastique: A new textured copolymer microparticle promises permanence in soft-tissue augmentation. Plast Reconstr Surg 1991; 87: 693. https://doi.org/10.1097/00006534-199104000-00014
Lemperle G, Romano JJ and Busso M. Soft tissue augmentation with Artecoll: 10-year history, indications, techniques, and complications. Dermatol Surg 2003; 29: 573. https://doi.org/10.1097/00042728-200306000-00004
Broder KW and Cohen SR. An overview of permanent and semipermanents fillers. Plast Reconstr Surg 2006; 118(Suppl): 7S. https://doi.org/10.1097/01.prs.0000234900.26676.0b
Rauso R, Freda N, Parlato V, Gherardini G, Amore R and Tartaro G. Polyacrylamide gel injection for treatment of human immunodeficiency virus-associated facial lipoatrophy: 18 months follow-up. Dermatol Surg 2011. https://doi.org/10.1111/j.1524-4725.2011.02131.x
Rauso R, Gherardini G, Greco M and Tartaro G. Is buffalo hump fat the perfect filler for facial wasting rehabilitation? Reflection on three cases. Eur J Plast Surg 2011.
Rauso R, Curinga G, Santillo V, Corvo G and Tartaro G. Comparison between lipofilling and a non resorbable filler for facial wasting rehabilitation in HIV+ patients. J Craniofac Surg. 2011; 22(5): 1684-8. https://doi.org/10.1097/SCS.0b013e31822e5cf8
Neuber F. Fettransplantation Chir Kongr Verhandl Dtsch. Gesellsch Chir 1893; 22: 66.
Fischer A and Fischer GM. Revised technique for cellulitis fat: Reduction in riding breeches deformity. Bull Int Acad Cosmet Surg 1977; 2: 40.
Illouz YG. The fat cell "graft": A new technique to fill depressions. Plast Reconstr Surg 1986; 78: 122. https://doi.org/10.1097/00006534-198607000-00028
Asken S. Liposuction Surgery and Autologous Fat Transplantation. Norwalk, Conn.: Appleton & Lange 1988.
Coleman SR. Structural fat grafting. In F. Nahai (Ed.), The Art of Aesthetic Surgery: Principles and Techniques. St. Louis: Quality Medical 2005; 289-363.
Davison SP, Timpone J and Hannan CM. Surgical algorithm for management of HIV lipodystrophy. Plast Reconstr Surg 2007; 120: 1843. https://doi.org/10.1097/01.prs.0000267341.14550.a7
Guaraldi G, De Fazio D, Orlando G, Murri R, Wu A, Guaraldi P, et al. Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. Clin Infect Dis 2004; 40(2): e13-5. https://doi.org/10.1086/426686
Rauso R, Gherardini G, Parlato V, Amore R and Tartaro G. Polyacrylamide Gel for Facial Wasting Rehabilitation: How many milliliters per session? Aesthetic Plast Surg 2011.
[Epub ahead of print].
Yang Y, Sitoh YY, Tha NO and Paton NI. Facial fat volume in HIV-infected patients with lipoatrophy. Antiviral Ther 2005; 10: 575-581.
Rauso R. 5-Year Study of a Polyacrylamide Hydrogel-Based Filler for Rehabilitation of HIV-Related Facial Lipoatrophy. Aesthete Surg J 2015; 7: pii: sjv036.
[Epub ahead of print].
Rauso R, Tartaro G, Freda N, Rusciani A and Curinga G. A facial marker in facial wasting rehabilitation. J Drugs Dermatol 2012; 11(2): 202-8.
Talmor M, Hoffman LA and LaTrenta GS. Facial atrophy in HIV-related fat redistribution syndrome: Anatomic evaluation and surgical reconstruction. Ann Plast Surg 2002; 49: 11-18. https://doi.org/10.1097/00000637-200207000-00002
Mori A, Lo Russo G, Agostini T, Pattarino J, Vichi F and Dini M. Treatment of human immunodeficiency virus-associated facial lipoatrophy with lipofilling and submalar silicone implants. J Plast Reconstr Aesthet Surg 2006; 59: 1209-1216. https://doi.org/10.1016/j.bjps.2005.12.047
Claude O, Domergue Than Trong E, Blanc R, Ascher B, Bagot M, et al. Traitment des lipoatrophies facials utilisant des implants de Medpor en polyethylene poreux. Ann Chir Plast Esthet 2009; 54: 21-28. https://doi.org/10.1016/j.anplas.2008.05.009
Serra-Renom JM and Fontdevila J. Treatment of facial atrophy related to treatment with protease inhibitors by autologous fat injection in patients with Human Immunodeficiency Virus infection. Plast Reconstr Surg 2004; 114: 551-5. https://doi.org/10.1097/01.PRS.0000128427.54445.63
Negredo E, Higueras C, Adell X, Martinez JC, Martinez E, Puig J, et al. Reconstructive treatment for antiretroviralassociated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances. AIDS Patient Care STDS 2006; 20(12): 829-837. https://doi.org/10.1089/apc.2006.20.829
Sturm LP, Cooter RD, Mutimer KL, Graham JC and Maddern GJ. A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy. AIDS Patient Care STDS 2009; 23: 699-714. https://doi.org/10.1089/apc.2008.0230
Ho¨nig J. Cheek augmentation with Bio-Alcamid in facial lipoatrophy in HIV seropositive patients. J Craniofac Surg 2008; 19(4): 1085-1088. https://doi.org/10.1097/SCS.0b013e31811eda9c
Karim RB, de Lint CA, van Galen SR, van Rozelaar L, Nieuwkerk PT, et al. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients. Aesthetic Plast Surg 2008; 32(6): 873- 878. https://doi.org/10.1007/s00266-008-9189-8
De Santis G, Jacob V, Baccarani A, Pedone A, Pinelli M, et al. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: a 2 year clinical experience. Plast Reconstr Surg 2008; 121: 644- 653. https://doi.org/10.1097/01.prs.0000298108.46379.15
Negredo E, Puig J, Aldea D, Medina M, Estany C, et al. Fouryear safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy. AIDS Res Hum Retrovir 2009; 25: 451-455. https://doi.org/10.1089/aid.2008.0230
De Santis G, Pignatti M, Baccarani A, Pedone A, Spaggiari A, et al. Long-term efficacy and safety of polyacrylamide hydrogel injection in the treatment of human immunodeficiency virus-related facial lipoatrophy: a 5-year follow-up. Plast Reconstr Surg 2012; 129(1): 101-9. https://doi.org/10.1097/PRS.0b013e3182362142
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
